Open AccessAssociation of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community
Author(s) -
Ronald C. Petersen,
Heather J. Wiste,
Stephen D. Weigand,
Walter A. Rocca,
Rosebud O. Roberts,
Michelle M. Mielke,
Val J. Lowe,
David S. Knopman,
V. Shane Pankratz,
Mary M. Machulda,
Yonas E. Geda,
Clifford R. Jack
Publication year - 2015
Publication title -
jama neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.298
H-Index - 231
eISSN - 2168-6157
pISSN - 2168-6149
DOI - 10.1001/jamaneurol.2015.3098
Subject(s) - pittsburgh compound b , standardized uptake value , positron emission tomography , medicine , longitudinal study , biomarker , dementia , amyloid (mycology) , cognition , magnetic resonance imaging , population , clinical trial , oncology , alzheimer's disease , alzheimer's disease neuroimaging initiative , cognitive decline , psychology , pathology , disease , nuclear medicine , psychiatry , radiology , biochemistry , chemistry , environmental health
The role of amyloid in the progression of Alzheimer disease (AD) pathophysiology is of central interest to the design of randomized clinical trials. The presence of amyloid has become a prerequisite for enrollment in several secondary prevention trials for AD, yet the precise effect of elevated amyloid levels on subsequent clinical and biomarker events is less certain.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom